Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem
6/12/2014 7:46:15 AM
BASEL, Switzerland, June 12, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) has initiated a phase 1 clinical study with its Gram-negative antibiotic BAL30072 evaluating the safety, tolerability and pharmacokinetics of multiple-ascending doses of intravenously administered BAL30072 in combination with meropenem, an antibiotic of the carbapenem class.
Help employers find you! Check out all the jobs and post your resume.
comments powered by